Limitations of Experimental Human Abuse Liability ... - immpact

More documents

Recommendations

Info

6. What constitutes a clinically significantreduction in abuse liability of an ADF?* ***How does one evaluate the “lowered” abuse liability of the ER productwhen it produces more liking than placebo? Maybe taking two of theER tablets would elevate liking to the same degree as the IR product.
6. What constitutes a clinically significantreduction in abuse liability of an ADF?*** *
Page 1 and 2: Limitations of Experimental HumanAb
Page 3 and 4: Issues Relating to Human ALA ofOpio
Page 5 and 6: An Added Component to Traditional A
Page 7 and 8: Major Issues Related ToExtractabili
Page 9 and 10: Extractability (Benchtop) Testing:T
Page 11 and 12: 2. What is the appropriate subject
Page 13 and 14: 2. What is the appropriate subject
Page 15 and 16: 3. When doing IN and IV ALA, should
Page 17 and 18: 3. When doing IN and IV ALA, should
Page 19 and 20: 4. What kind of ALA testing needs t
Page 21 and 22: 5. Latency to peak positive effects
Page 23 and 24: The issue of weighting due to rate
Page 25: 6. What constitutes a clinically si
Page 29 and 30: Does ALA have predictive validity?
Page 31 and 32: Have ALA instruments been validated
Page 33 and 34: CPDD Expert Panels recommendation
Page 35 and 36: • BipolarDrug liking- VAS: 0= dis
Page 37: Acknowledgments• Kenzie Preston,

Limitations of Experimental Human Abuse Liability ... - immpact

Create successful ePaper yourself

Delete template?

Save as template?